Physician profile
Nadia N Bowling
NPI 1992167746
$4,025.95
in general payments reported to CMS, 2019-2025
22 companies · $894 in 2025
The $894 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $400 · 2023: $1,034 · 2024: $1,699 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,626.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,834.46 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Argenx US, INC. | $378.65 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $271.84 | 2022-2025 | |
| Ucb, INC. | $261.89 | 2022-2024 | Briviact, Rystiggo |
| Catalyst Pharmaceuticals, INC. | $208.71 | 2023-2025 | Fycompa |
| Abbott Laboratories | $134.03 | 2024 | Amplatzer Talisman |
| Pfizer INC. | $128.95 | 2023-2025 | |
| Lundbeck LLC | $111.25 | 2023-2024 | Vyepti |
| Lilly USA, LLC | $103.55 | 2022-2025 | Reyvow, Emgality, Kisunla |
| Eisai INC. | $84.00 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $81.69 | 2025 | Ponvory |
| Genentech USA, INC. | $80.10 | 2023-2024 | Ocrevus, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $65.91 | 2023-2024 | Austedo Xr, Ajovy |
| Alexion Pharmaceuticals, INC. | $49.60 | 2022-2024 | Ultomiris, Soliris |
| Genzyme Corporation | $47.79 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $39.60 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Mdd US Operations, LLC | $38.37 | 2024 | Apokyn |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.40 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $19.35 | 2024 | Lumryz |
| Amneal Pharmaceuticals LLC | $18.59 | 2024 | Crexont |
| Csl Behring | $16.60 | 2022 | |
| Acadia Pharmaceuticals INC | $13.62 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Bowling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.